SEC Form SC 13G/A filed by Neogen Corporation (Amendment)
$NEOG
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2025 | Outperform → Mkt Perform | William Blair | |
| 12/19/2024 | $15.00 | Buy | Guggenheim |
| 6/16/2023 | $22.00 | Overweight | Wells Fargo |
| 11/22/2022 | Mkt Perform → Outperform | William Blair | |
| 7/12/2022 | $25.00 | Neutral | Piper Sandler |
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4/A - NEOGEN CORP (0000711377) (Issuer)
Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.
Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Thursday, April 9, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time. During the call, Neogen management will provide a financial overview and business update of the company's performance for the third-quarter of fiscal year 2026. The conference call can be accessed by dialing: Toll-Free - North America: (1) 888-660-6264 International: (+1) 646-517-3975 Conference ID: 70064# The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "E
Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today it has entered into a definitive agreement to sell its global genomics business to Zoetis Inc. ("Zoetis"), the world's leading animal health company, for $160 million, subject to customary closing adjustments. The planned divestiture, which had been previously announced, was part of the company's portfolio review strategy to simplify the business and focus on core strategic markets. The transaction is expected to close by the end of the first half of the Company's 2027 fiscal year, subject to regulatory approval and customary closing conditions. The net proceeds from the transaction are expected
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
8-K - NEOGEN CORP (0000711377) (Filer)
SCHEDULE 13G/A - NEOGEN CORP (0000711377) (Subject)
10-Q - NEOGEN CORP (0000711377) (Filer)
William Blair downgraded Neogen from Outperform to Mkt Perform
Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00
Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00
Neogen Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.
Neogen® Corporation (NASDAQ:NEOG), a global leader of food safety solutions, is pleased to announce the appointment of Bryan Riggsbee as its new Chief Financial Officer effective November 3, 2025. Riggsbee will oversee Neogen's global finance organization and join the company's Executive Leadership Team, reporting directly to Chief Executive Officer Mike Nassif. To ensure a smooth transition, David Naemura is expected to remain with the Company until the end of the calendar year. Riggsbee brings over 25 years of financial leadership experience across the diagnostics and healthcare industries. He joins Neogen from bioMérieux where he served as Chief Financial Officer of its $2 billion Nort
Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that William Boehm has chosen to retire from the Company's Board of Directors, effective October 23, 2025. Mr. Boehm has served on Neogen's Board since 2011 and currently serves on the Compensation & Talent Management Committee and chairs the Audit Committee. "On behalf of the entire Board and leadership team, I want to express our deep gratitude to Bill for his many years of dedicated service to Neogen," said James C. Borel, Chair of the Neogen Board of Directors. "Bill's insight, guidance, and commitment to our mission have been invaluable in shaping Neogen's path forward. His contributions
Neogen® Corporation (NASDAQ:NEOG) will issue its third-quarter earnings release before the opening of the market on Thursday, April 9, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time. During the call, Neogen management will provide a financial overview and business update of the company's performance for the third-quarter of fiscal year 2026. The conference call can be accessed by dialing: Toll-Free - North America: (1) 888-660-6264 International: (+1) 646-517-3975 Conference ID: 70064# The live webcast can be accessed through Neogen's Investor Relations webpage, neogen.com/investor-relations, under the "E
Revenue of $224.7 million, a decrease of 2.8% YoY; Core growth1 increased 2.9% YoY Net loss of $15.9 million; Adjusted Net Income1 of $22.6 million Adjusted EBITDA1 of $48.7 million; Adjusted EBITDA margin1 increased 470 bps sequentially Company hires key senior commercial leaders Petrifilm manufacturing transition remains on track Raising FY 2026 revenue and Adjusted EBITDA guidance 1 Non-GAAP financial measures; see explanations and reconciliations that follow Neogen Corporation (NASDAQ:NEOG) announced today the results of the second quarter ended November 30, 2025. "I am exceptionally proud of the Neogen team as we have initiated the first phase of our strategic tr
Neogen® Corporation (NASDAQ:NEOG) will issue its second-quarter earnings release before the opening of the market on January 8, 2026. Executives from the company will host a webcast and conference call later that morning, beginning at 8:00 a.m. Eastern time, to discuss the financial results. The conference call can be accessed by dialing: Toll-Free - North America: 1-800-549-8228 International: (+1) 646-564-2877 Conference ID: 82072 The live webcast can be accessed through Neogen's Investor Relations webpage, investors.neogen.com, under the "Events & Presentations" subheading. A replay of the conference call and webcast will be available shortly following the conclusion of the call and c
SC 13G - NEOGEN CORP (0000711377) (Subject)
SC 13G - NEOGEN CORP (0000711377) (Subject)
SC 13G/A - NEOGEN CORP (0000711377) (Subject)